Dimerix Limited appointed Dr. Nina Webster as CEO and Managing Director of the Company, effective as at August 27, 2018, and that Mrs. Kathy Harrison will move into the newly created role of Chief Operating Officer (COO). Both appointments are in line with the Company's plans to bolster its executive leadership as it moves toward the imminent commencement of two phase 2 human clinical trials for lead program, DMX-200. Dr. Webster brings over 25 years of global experience in both biotechnology and pharmaceuticals, beginning her career in new product development with Wyeth Pharmaceuticals (now part of Pfizer) in the UK before moving to Australia. She has held a number of senior executive leadership roles and has also held responsibility for business development, investor relations and prosecution of intellectual property matters, as well as leading and managing the
strategic, scientific and operational aspects of product development. In her most recent role, Nina was Commercial Director of Acrux Limited, where she was responsible for the strategic identification, development and maintenance of commercial partnerships globally, the intellectual property portfolio and investor relations. Whilst at Acrux she had a lead role in multiple commercial transactions with global pharmaceutical companies that collectively have netted over $300 million in revenue to date, and she prosecuted several complex US-based intellectual property matters. Prior to that she was the Director of Commercialisation & IP for Immuron. As previously advised, with this appointment, Kathy Harrison will now transition into the COO role allowing focus on the important task of executing clinical programs for which she has demonstrated enormous talent.